Search is Powered by Google
Lymphoma / Leukemia News

Non-Hodgkin Lymphoma Patients' Survival Affected By Socioeconomic And Treatment Factors

Main Category: Lymphoma / Leukemia
Also Included In: Lymphology/Lymphedema;  Seniors / Aging;  Radiology / Nuclear Medicine
Article Date: 21 Oct 2008 - 4:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient's risk of dying. That is the finding of a new study published in the December 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study reveals that poorer socioeconomic status increases a patient's risk of dying, while receiving chemotherapy reduces the risk.

NHL is a common type of cancer in the elderly. Its incidence has been increasing over the past several decades, and Caucasians have higher incidence and death rates related to the disease than patients in other ethnic groups. Newer treatments for NHL have become available in recent years; however, studies have not addressed ethnic disparities in survival as they relate to treatment, diagnosis, socioeconomic status, or other factors.

To investigate the issue, Dr. Xianglin Du of the University of Texas School of Public Health in Houston and colleagues analyzed SEER (Surveillance, Epidemiology and End Results)-Medicare linked data for more than 13,000 patients diagnosed at age 65 or older between 1992 and 1999. The metropolitan areas of San Francisco/Oakland, Detroit, Atlanta, Seattle, Los Angeles County, San Jose/Monterey, and the states of Connecticut, Iowa, New Mexico, Utah, and Hawaii were included in this study.

Dr. Du and his team analyzed data related to survival, socioeconomic status, treatment (chemotherapy or radiation), tumor factors (stage and type of NHL), the presence of other diseases or conditions, and other characteristics such as age, race, marital status, and geographic area.

The investigators found that receiving chemotherapy was associated with prolonged survival in patients with NHL and that elderly Caucasian patients with NHL were more likely to receive chemotherapy (52.4 percent) compared with African-Americans (43.2 percent). Also, poor socioeconomic status was significantly associated with increased risk of mortality, and there were a larger proportion of African-American patients living in poor communities compared with other ethnicities. No significant differences in the risk of death were seen between African-Americans and Caucasians after controlling for factors such as treatment and socioeconomic status.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Article: "Ethnic variations in diagnosis, treatment, socioeconomic status and survival in a large population-based cohort of elderly patients with Non-Hodgkin's Lymphoma." Michael Wang, Keith D. Burau, Shenying Fang, Harry Wang, and Xianglin L. Du. CANCER; Published Online: October 20, 2008 (DOI: 10.1102/cncr.23914); Print Issue Date: December 1, 2008.

Source: David Sampson
American Cancer Society




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Case Of Patient "Cured" Of HIV Baffles Doctors
14 Nov 2008
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been "cured" by a bone marrow transplant given to treat his acute myeloid leukemia...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating Lymphoma Early image Treating Lymphoma Early

Non-Hodgkin's lymphoma is a cancer of the immune system. First-line treatment options include radiation therapy, chemotherapy, immunotherapy, radioimmunotherapy and stem cell transplant. How do you figure out which is right for you...

View more videos...